admin

August 19, 2025

Data Indicate OBM’s OBM1701 Diffuses into the Retina and RPE and Effectively Alleviates Choroidal Neovascularisation in wet-AMD Animal Model after Topically Applied Has Been Published on An Association for Research in Vision and Ophthalmology (ARVO) Official Journal – 19th August 2025

Oculus Biomed Limited (“OBM”) is pleased to announce that the research data which covers OBM’s OBM1701, its leading drug candidate for the treatment of wet-AMD, has […]
July 30, 2025

OBM Was Invited by Our Legal Advisor Firm Steinepreis Paganin to Attend IPO Network’s Exclusive Event in Melbourne
30th July 2025

Oculus Biomed Limited (“OBM”) is invited by its legal advisor, Steinepreis Paganin (“SP”), to attend a function held by the IPO Network, on the evening of […]
July 27, 2025

OBM Attends BioAsia-Taiwan Conference and ACRO Biomedical Announces to Outlicense the Market Rights in 10 ASEAN Countries of its Biocompatible Artificial Cornea, ABCcolla Collagen Ophthalmic Matrix, to Vietnam’s CT Group
23th ~ 27 July 2025

ACRO Biomedical’s Chairman & CEO Dr Hsieh (left) & OBM’s CSO Dr Jiang (right) met for business discussion at 2025 BioAsia Taiwan Conference. ACRO Biomedical’s Chairman […]
July 14, 2025

Professor Mark Daniell Joined to OBM Scientific Board
14th July 2025

We highly welcome Professor Mark Daniell to join the OBM Scientific Board. He brings significant experience of medical research and clinical surgery to the company.   […]
March 14, 2025

Our Partner ACRO Biomedical Co., Ltd. Receives Approval for Its Biocompatible Cornea from Taiwan FDA, the Department of Health and Welfare
14th March 2025

  Our strategic partner and major shareholder, ACRO Biomedical Co., Ltd., a public listed company on Taiwan Stock Exchange and one of the Taiwan’s leading biomedical […]
November 27, 2023

Mr Roger McPherson appointed CFO / Company Secretary
27 Nov 2023

OBM is delighted to welcome Roger to the executive team. He brings significant technical skill and industry experience to the company. Roger has more than 30 […]
November 1, 2023

AusBiotech conference Brisbane
1 – 3 Nov 2023

OBM recently attended Australias premier biotechnology conference in Brisbane – represented by CEO Andrew Coloretti & Non-Executive Director Michelle Gallaher. The conference included valuable one-on-one private […]
October 9, 2023

Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies.
11 Oct 2023

Oculus BioMed (OBM) an ophthalmology focused biotechnology company, entered into a collaboration agreement with CERA – Centre for Eye Research Australia regarding the development of a therapeutic […]
October 1, 2023

Ms Michelle Gallaher appointed Non-Executive Director
01 Oct 2023

OBM is delighted to welcome Michelle to the Board. She is an exceptional person and professional and brings significant industry experience and skill to the company. […]